GAIN THERAPEUTICS, INC Increase (Decrease) in Deferred Liabilities
GAIN THERAPEUTICS, INC (GANX) reported Increase (Decrease) in Deferred Liabilities of $22.45 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2026-08-11
- GAIN THERAPEUTICS, INC increase (decrease) in deferred liabilities for the quarter ending 2025-12-31 was -$14.84K.
- GAIN THERAPEUTICS, INC increase (decrease) in deferred liabilities for the quarter ending 2025-09-30 was -$18.24K, a 7828.39% decline year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in deferred liabilities for the quarter ending 2025-06-30 was -$206.36K.
- GAIN THERAPEUTICS, INC increase (decrease) in deferred liabilities for the quarter ending 2025-03-31 was -$88.63K, a 312.05% decline year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in deferred liabilities for fiscal 2025 was -$328.07K.
- GAIN THERAPEUTICS, INC increase (decrease) in deferred liabilities for fiscal 2024 was -$854.71K, a 178.75% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC increase (decrease) in deferred liabilities for fiscal 2023 was $1.09M.
- GAIN THERAPEUTICS, INC increase (decrease) in deferred liabilities for fiscal 2022 was -$208.34K, a 700.39% decline from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month | Increase (Decrease) in Deferred Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.45K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | -$14.84K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$33.08K derived: sum of 2 quarters · filed 2026-03-26 | -$239.44K derived: sum of 3 quarters · filed 2026-08-11 | -$328.07K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$18.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$224.60K derived: sum of 2 quarters · filed 2026-08-11 | -$313.23K 10-Q · filed 2025-11-12 | -$1.21M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$206.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$294.99K 10-Q · filed 2026-08-11 | -$1.19M derived: sum of 3 quarters · filed 2026-08-11 | -$1.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$88.63K 10-Q · filed 2026-05-11 | -$985.20K derived: sum of 2 quarters · filed 2026-05-11 | -$984.96K derived: sum of 3 quarters · filed 2026-05-11 | -$985.14K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$896.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$896.33K derived: sum of 2 quarters · filed 2026-03-26 | -$896.51K derived: sum of 3 quarters · filed 2026-03-26 | -$854.71K 10-K · filed 2026-03-26 |
| 2024-09-30 | $236.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $55.00 derived: sum of 2 quarters · filed 2025-11-12 | $41.85K 10-Q · filed 2025-11-12 | -$336.57K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$181.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $41.62K 10-Q · filed 2025-08-12 | -$336.80K derived: sum of 3 quarters · filed 2025-08-12 | -$466.08K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $41.80K 10-Q · filed 2025-05-14 | -$336.62K derived: sum of 2 quarters · filed 2025-05-14 | -$465.90K derived: sum of 3 quarters · filed 2025-05-14 | $1.18M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$378.42K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$507.70K derived: sum of 2 quarters · filed 2025-03-27 | $1.14M derived: sum of 3 quarters · filed 2025-03-27 | $1.09M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$129.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.52M derived: sum of 2 quarters · filed 2024-11-14 | $1.46M 10-Q · filed 2024-11-14 | $1.46M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.59M 10-Q · filed 2024-08-08 | $1.59M derived: sum of 3 quarters · filed 2024-08-08 | $1.57M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$55.18K 10-Q · filed 2024-05-14 | -$55.79K derived: sum of 2 quarters · filed 2024-05-14 | -$77.22K derived: sum of 3 quarters · filed 2024-05-14 | -$200.21K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$608.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$22.04K derived: sum of 2 quarters · filed 2024-03-26 | -$145.03K derived: sum of 3 quarters · filed 2024-03-26 | -$208.34K 10-K · filed 2024-03-26 |
| 2022-09-30 | -$21.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$144.43K derived: sum of 2 quarters · filed 2023-11-14 | -$207.74K 10-Q · filed 2023-11-14 | -$261.24K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$186.31K 10-Q · filed 2023-08-10 | -$239.81K derived: sum of 3 quarters · filed 2023-08-10 | -$282.64K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$63.31K 10-Q · filed 2023-05-12 | -$116.82K derived: sum of 2 quarters · filed 2023-05-12 | -$159.64K derived: sum of 3 quarters · filed 2023-05-12 | $32.46K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$53.51K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$96.33K derived: sum of 2 quarters · filed 2023-03-23 | $95.77K derived: sum of 3 quarters · filed 2023-03-23 | $34.70K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$42.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $149.27K derived: sum of 2 quarters · filed 2022-11-10 | $88.21K 10-Q · filed 2022-11-10 | $40.49K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $192.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $131.03K 10-Q · filed 2022-08-08 | $83.31K derived: sum of 3 quarters · filed 2022-08-08 | $3.01K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$61.06K 10-Q · filed 2022-05-16 | -$108.79K derived: sum of 2 quarters · filed 2022-05-16 | -$189.09K derived: sum of 3 quarters · filed 2022-05-16 | -$135.97K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$47.72K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | -$128.02K derived: sum of 2 quarters · filed 2022-03-25 | -$74.91K derived: sum of 3 quarters · filed 2022-03-25 | -$129.31K 10-K · filed 2022-03-25 |
| 2020-09-30 | -$80.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$27.19K derived: sum of 2 quarters · filed 2021-11-12 | -$81.59K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $53.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$1.29K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$54.41K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |